476 related articles for article (PubMed ID: 33991294)
1. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System.
Chen Y; Mazur C; Luo Y; Sun L; Zhang M; McCampbell A; Tomassy GS
J Vis Exp; 2019 Oct; (152):. PubMed ID: 31736489
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration.
Jafar-Nejad P; Powers B; Soriano A; Zhao H; Norris DA; Matson J; DeBrosse-Serra B; Watson J; Narayanan P; Chun SJ; Mazur C; Kordasiewicz H; Swayze EE; Rigo F
Nucleic Acids Res; 2021 Jan; 49(2):657-673. PubMed ID: 33367834
[TBL] [Abstract][Full Text] [Related]
5. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
Biliouris K; Gaitonde P; Yin W; Norris DA; Wang Y; Henry S; Fey R; Nestorov I; Schmidt S; Rogge M; Lesko LJ; Trame MN
CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):581-592. PubMed ID: 30043511
[TBL] [Abstract][Full Text] [Related]
6. A single-cell map of antisense oligonucleotide activity in the brain.
Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
[TBL] [Abstract][Full Text] [Related]
7. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
[TBL] [Abstract][Full Text] [Related]
8. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
10. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides.
Linninger AA; Barua D; Hang Y; Iadevaia S; Vakilynejad M
Front Physiol; 2023; 14():1130925. PubMed ID: 37334053
[TBL] [Abstract][Full Text] [Related]
12. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
[TBL] [Abstract][Full Text] [Related]
13. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
[TBL] [Abstract][Full Text] [Related]
14. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
Mazur C; Powers B; Zasadny K; Sullivan JM; Dimant H; Kamme F; Hesterman J; Matson J; Oestergaard M; Seaman M; Holt RW; Qutaish M; Polyak I; Coelho R; Gottumukkala V; Gaut CM; Berridge M; Albargothy NJ; Kelly L; Carare RO; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31619586
[TBL] [Abstract][Full Text] [Related]
15. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
[TBL] [Abstract][Full Text] [Related]
16. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS.
Wahlestedt C; Khorkova O
Cell Mol Neurobiol; 2021 Jul; 41(5):849-853. PubMed ID: 32656646
[TBL] [Abstract][Full Text] [Related]
17. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
18. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
19. Development of a simple, rapid, and robust intrathecal catheterization method in the rat.
Mazur C; Fitzsimmons B; Kamme F; Nichols B; Powers B; Wancewicz E
J Neurosci Methods; 2017 Mar; 280():36-46. PubMed ID: 28163066
[TBL] [Abstract][Full Text] [Related]
20. Save Your Maximum Tolerated Dose: How to Diagnose Procedure-Related Spinal Cord Lesions After Lumbar Intrathecal Bolus Administration of Oligonucleotides in Cynomolgus Monkeys.
Korte S; Luft J; von Keutz A; Runge F; Mecklenburg L; Wozniak MM; Zander S; Ludwig FT; Pajaziti B; Romeike A; Korytko P
Int J Toxicol; 2020; 39(6):510-517. PubMed ID: 32856507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
